BPC-157 and Hemorrhoids: What Studies Report

The short version: among the verified papers reviewed for this page, none studied BPC-157 in hemorrhoids, hemorrhoidal disease, or any model of anorectal venous cushion enlargement. The interest in this pairing appears to be inferential: BPC-157 has been studied extensively in rodent models of gastrointestinal injury and wound repair, and readers reasonably ask whether that literature says anything about a common anorectal condition. This page describes what the published work actually covered, what endpoints researchers measured, and where the evidence stops.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any symptom, diagnosis or treatment decision. Nothing here describes a protocol, and BPC-157 is not an approved drug for any condition.

Why hemorrhoids and BPC-157 get searched together

Hemorrhoidal disease involves engorgement and prolapse of the anorectal vascular cushions, often with mucosal fragility, bleeding, inflammation of overlying tissue, and — in some cases — fissures, thrombosis or fistula-in-ano as separate but co-occurring problems. Two strands of the BPC-157 literature superficially touch those themes.

First, the peptide has been characterised as a gastric pentadecapeptide with activity across the gastrointestinal tract. A 2018 review framed BPC-157 alongside standard angiogenic growth factors and drew explicit parallels between gastrointestinal tract healing and healing in tendon, ligament, muscle and bone, arguing for a shared cytoprotective mechanism across tissues (PMID 29998800). Second, a 2021 review collected the wound-healing literature, describing reported effects on skin and other injured tissues in animal models (PMID 34267654).

Neither review reported a hemorrhoid model. The inference from "gastrointestinal healing in rats" to "hemorrhoidal symptoms in humans" is a large one, and the literature does not bridge it.

What the gastrointestinal literature actually examined

Mucosal injury, anastomoses and fistulas

The closest anatomical relatives to hemorrhoid research in the verified set are the fistula papers. A 2020 review described BPC-157 therapy in fistula healing, covering experimental fistula models across the gastrointestinal tract and reporting closure or improved healing of these abnormal epithelial-lined tracts in animals (PMID 32329684). Fistula-in-ano is a distinct condition from hemorrhoids, though both are treated by colorectal surgeons; a reader should not read fistula data as hemorrhoid data.

The 2018 gastrointestinal review discussed healing of the tract in the context of angiogenic signalling and described BPC-157 as acting without the growth-factor-specific carrier requirements that limit standard angiogenic agents (PMID 29998800). A 2025 literature and patent review catalogued the breadth of reported gastrointestinal, musculoskeletal and neurological activity across preclinical publications and patent filings, and characterised the molecule as multifunctional (PMID 40005999).

Endpoints researchers used

Across these reviews, the endpoints reported were histological and functional rather than symptomatic in the way hemorrhoid trials are scored. Typical measures included lesion area, granulation tissue and re-epithelialisation, vessel formation, tensile or bursting strength at anastomoses, and survival of experimental animals. Hemorrhoid trials in humans, by contrast, use bleeding frequency, prolapse grade, pain scores, and recurrence after procedures. No verified paper reported any of those hemorrhoid-specific endpoints.

Human evidence: what exists and what it covered

Human publications in the verified set are few, small, and unrelated to anorectal disease.

• Intravenous safety pilot (2025). Researchers examined the safety of intravenous BPC-157 infusion in humans in a pilot study, reporting on tolerability rather than efficacy in any disease (PMID 40131143).
• Knee pain (2021). A report described intra-articular injection of BPC 157 for multiple types of knee pain, with symptom outcomes reported in a small clinical series (PMID 34324435).
• Interstitial cystitis (2024). A pilot study assessed the effect of BPC-157 on symptoms in patients with interstitial cystitis, a bladder mucosal pain condition (PMID 39325560).

The interstitial cystitis pilot is sometimes cited in online discussions as evidence for mucosal conditions generally. It is worth being precise: that study enrolled patients with a defined bladder syndrome and reported symptom measures in that population (PMID 39325560). It reported nothing about hemorrhoidal bleeding, prolapse or anal pain.

Preclinical soft-tissue work often quoted by proxy

Because hemorrhoid-specific data do not exist, discussion often falls back on the wider soft-tissue literature. A 2011 study reported that the promoting effect of pentadecapeptide BPC 157 on tendon healing involved tendon outgrowth, cell survival and cell migration in experimental systems (PMID 21030672). A 2019 review summarised the peptide's described role in accelerating musculoskeletal soft tissue healing across animal models (PMID 30915550). A 2022 review described work on the central nervous system, again largely preclinical (PMID 34380875).

These are mechanistically interesting but categorically different tissues. Tendon outgrowth assays say nothing about venous cushion engorgement, and researchers in those papers did not claim otherwise (PMID 21030672).

How reviewers judged the overall quality of evidence

Two 2025 papers assessed the evidence base directly rather than summarising individual findings.

A systematic review of emerging use in orthopaedic sports medicine screened the published literature and concluded that the available human evidence was sparse and largely preclinical, with methodological limitations across studies (PMID 40756949). A narrative review titled "Regeneration or Risk?" examined BPC-157 for musculoskeletal healing and discussed the gap between promotional enthusiasm and controlled human data, alongside regulatory status and product-quality issues (PMID 40789979).

Both conclusions apply with more force to hemorrhoids than to musculoskeletal indications, because in musculoskeletal use there is at least some human reporting (PMID 34324435), whereas for hemorrhoidal disease there is none in the verified set.

Safety and Tolerability: What Studies Report

The verified literature contains limited systematic safety reporting.

• The 2025 intravenous pilot was designed specifically around safety of infusion in humans and reported on that question in a small sample (PMID 40131143).
• The 2025 systematic review in orthopaedic sports medicine noted that adverse-event reporting across included studies was inconsistent and that long-term human safety data were lacking (PMID 40756949).
• The 2025 narrative review raised risk considerations explicitly, including the absence of regulatory approval and uncertainty about unregulated product purity and content (PMID 40789979).
• Reviews of preclinical work described a wide reported activity profile without established human dose-ranging (PMID 40005999).

Because no hemorrhoid study exists, there is also no data on tolerability in inflamed anorectal tissue, on bleeding risk in a condition defined partly by bleeding, or on interactions with standard care such as fibre, topical agents, rubber-band ligation or surgery.

Key limitations a reader should weigh

1. Indication mismatch. Gastrointestinal healing models studied mucosal ulcers, anastomoses and fistulas — not hemorrhoidal vascular cushions (PMID 29998800, PMID 32329684).
2. Species and translation. The bulk of the cited work was animal or in-vitro (PMID 30915550, PMID 21030672).
3. Small, uncontrolled human reports. Pilot designs with few participants cannot establish efficacy for any condition (PMID 39325560, PMID 40131143).
4. Publication concentration. Reviewers have noted that much of the preclinical output comes from a narrow set of research groups, limiting independent replication (PMID 40756949).
5. Route uncertainty. The reviewed human work used intravenous or intra-articular administration; no verified study examined topical or rectal delivery (PMID 40131143, PMID 34324435).
6. Diagnostic overlap. Anorectal bleeding has many causes, some serious; the literature offers nothing on differentiating them and does not substitute for clinical evaluation.

Regulatory context

BPC-157 is not an approved medicine for hemorrhoids or any other condition in major jurisdictions, and reviewers in 2025 discussed its investigational and unapproved status alongside concerns about materials sold outside regulated supply chains (PMID 40789979). Research-use-only labelling denotes material not intended for human administration. This page does not provide legal advice.

Bottom line

The honest answer to "what do studies report about BPC-157 and hemorrhoids?" is: they do not report anything directly. What exists is a large preclinical body on gastrointestinal and soft-tissue repair (PMID 29998800, PMID 34267654), a fistula-focused review (PMID 32329684), three small human pilots in unrelated conditions, and two 2025 reviews that judged the human evidence base immature (PMID 40756949, PMID 40789979). Hemorrhoidal disease has well-studied conventional management pathways that a physician can discuss; the peptide literature is not part of that evidence base.

References

• BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing (Current Pharmaceutical Design, 2018)
• Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review (Pharmaceuticals, 2025)
• Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (HSS Journal, 2025)
• Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell and Tissue Research, 2019)
• Stable Gastric Pentadecapeptide BPC 157 and Wound Healing (Frontiers in Pharmacology, 2021)
• Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (Alternative Therapies in Health and Medicine, 2021)
• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (Current Reviews in Musculoskeletal Medicine, 2025)
• Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study (Alternative Therapies in Health and Medicine, 2024)
• Pentadecapeptide BPC 157 and the central nervous system (Neural Regeneration Research, 2022)
• The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Journal of Applied Physiology, 2011)
• Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy (Current Pharmaceutical Design, 2020)
• Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (Alternative Therapies in Health and Medicine, 2025)